Diabetes and vascular disease

References

• Hu G, Jousilahti P, Katoh S, Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and nondiabetic individuals with or without history of myocardial infarction. Diabetologia48(5), 856–861 (2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet364(9438), 937–952 (2004).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes: 2006.Diabetes Care29(Suppl. 1), S4–S42 (2006).
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham Study. JAMA21, 2035–2038 (1979).
   Google Scholar
• Kannel WB, McGee DL. Update on some epidemiological features of intermittent claudication: the Framingham Study. J. Am. Geriatr. Soc.33, 13–18 (1985).
   PubMed Web of Science ®Google Scholar
• Americal Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care26, 3333–3341 (2003).
   PubMed Web of Science ®Google Scholar
• Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med.141, 421–431 (2004).
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br. Med. J.332(7553), 73–78 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Prevalence of diabetes and impaired fasting glucose in adults – United States, 1999–2000. MMWR Morb. Mortal. Wkly Rep.52(55), 833–837 (2003).
   PubMedGoogle Scholar
• Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin. Sci. (London)112(7), 375–384 (2007).
   PubMed Web of Science ®Google Scholar
• Kanter JE, Johansson F, LeBoeuf RC et al. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Cir. Res.100(6), 769–781 (2007).
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. UKPDS, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Balkau B, Hu G, Qiao Q et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia47(12), 2118–2128 (2004).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med.353(25), 2643–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA290(4), 486–94 (2003).
   PubMed Web of Science ®Google Scholar
• Stettler C, Allemann S, Juni P et al. Glycemic control and macrovascular disease in Types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am. Heart J.152(1), 27–38 (2006).
   PubMed Web of Science ®Google Scholar
• Lindstrom J, Llanne-Parikka P, Peltonen M et al. Sustained reduction in the incidence of Type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet368(9548), 1673–1679 (2006).
   PubMed Web of Science ®Google Scholar
• Diabetes prevention program research group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet368, 1096–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) Study: interim findings on cardiovascular hospitalizations and deaths. N. Engl. J. Med. (2007). DOI:10.1056/NEJM oa073394.
   PubMed Web of Science ®Google Scholar
• Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol. Metab. Clin. North Am.35(3), 491–510, vii–viii (2006).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) Study. Diabetes Care29(6), 1220–1226 (2006).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndrome. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atrovastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet364(9435), 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. The ACCORD trial: a multidisciplinary approach to control cardiovascular risk in Type 2 diabetes mellitus. Pract. Diabetol.23, 6–11 (2004).
   Google Scholar
• El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr. Hypertens. Rep.6(3), 215–223 (2004).
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Review: Insulin and endothelin: an interplay contributing to hypertension development? J. Clin. Endocrinol. Metab.92(2), 379–385 (2007).
   Google Scholar
• Patel A, MacMohan S, Chalmers J et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet370(9590), 829–40 (2007).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome scientific statement: an American Heart Association/ National Heart, Lung and Blood Institute Scientific Statement. Executive summary. Circulation112(17), 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Franz MJ, Bantle JP, Beebe CA et al. American Diabetes Association. Nutrition principles and recommendation in diabetes. Diabetes Care27(Suppl. 1), S36–S46 (2004).
   PubMedGoogle Scholar
• Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation115, 114–126 (2007).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C et al. Blood Pressure Lowering Trialists’ Collboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165, 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Varughese GI, Lip GY. Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists’ collaboration meta-analysis. J. Hum. Hypertens.19, 851–853 (2005).
   Google Scholar
• Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patient with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation113, 2363–2372 (2006).
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patient with acute myocardial infarction). J. Am. Coll. Cardiol.44(3), E1–E211 (2004).
   PubMedGoogle Scholar
• Breeman A, Hordijk M, Lenzen M et al. Treatment decisions in stable coronary artery disease in a broad range of European practices. Insights from the Euro Heart Survey on coronary revascularization. J. Thor. Cardiovasc. Surg.132, 1001–1009 (2006).
   Google Scholar
• Barsness GW, Gersh BJ, Brooks MM, Frye R; BARI 2D Trial Investigators. Rationale for the revascularization arm of the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Am. J. Cardiol.97(12A), 31–40G (2006).
   Google Scholar
• Goldstein LB, Adams R, Becker K et al. Primary prevention of ischemic stroke. A statement for health care professionals from the stroke council of the American Heart Association. Stroke32, 280–293 (2001).
   PubMed Web of Science ®Google Scholar
• Goodney PP, Schermehorn MK, Powell RJ. Current status of carotid artery stenting. J. Vasc. Surg.43, 406–411 (2006).
   PubMedGoogle Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE subsutdy. Lancet355, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomized trial of a perindorpil-based blood- pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol-lowering in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Colwell JA. Aspirin therapy in diabetes (Technical review). Diabetes Care20, 1767–1771 (1997).
   PubMedGoogle Scholar
• Diener F, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet364, 331–337 (2004).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W et al. for the CHARISMA investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med.354, 1706–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation110, 738–743 (2004).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care26, 3333–3341 (2003).
   PubMed Web of Science ®Google Scholar
• Jude EB, Oyibo SO, Chalmers N et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care24, 1433–1437 (2001).
   PubMed Web of Science ®Google Scholar
• Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med.344, 1608–1621 (2001).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Rutherford RB; TASC Working Group. TransAtlantic Inter-Society Concensus (TASC), Management of peripheral arterial disease (PAD). J. Vasc. Surg.31, S1–S296 (2000).
   Google Scholar
• Loosemore T, Chalmers T, Dormandy J. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int. Angiol.13, 133–142 (1994).
   Google Scholar
• PROactive study executive committee and data and safety monitoring committee. Lancet367(9515), 982 (2006).
   Google Scholar
• Gray A, Clarke P, Farmer A, Holman R; United Kingdom Prospective Diabetes Study (UKPDS) Group. Implementing intensive control of blood glucose concentration and blood pressure in Type 2 diabetes in England: cost analysis (UKPDS 63). Br. Med. J.325(7389), 860 (2002).
   PubMed Web of Science ®Google Scholar
• Vijgen SM, Hoogendoom M, Baan CA, de Wit GA, Limburg W, Feenstra TL. Cost effectiveness of preventive interventions in Type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics24, 425–441 (2006).
   Google Scholar
• Minshall ME, Roze S, Palmer AJ et al. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and Type 2 diabetes mellitus in the United States. Clin. Ther.27, 940–950 (2005).
   PubMed Web of Science ®Google Scholar
• Blonde L, Rosenstock J, Triplitt C. What are incretins, and how will they influence the management of Type 2 diabetes? J. Manag. Care Pharm.12(7 Suppl. A), 2–12 (2006).
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care28, 1083–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with Type 2 diabetes. Diabetes Obes. Metab.8, 436–447 (2006).
   PubMed Web of Science ®Google Scholar
• Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of Type 2 diabetes. Diabetes Vasc. Dis. Res.3, 159–65 (2006).
   PubMedGoogle Scholar
• Davidson M. Global risk management in patients with Type 2 diabetes. Am. J. Cardiol.99(Suppl.), 41B–50B (2007).
   Web of Science ®Google Scholar